Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Medicis Pharmaceutical Corp    MRX

MEDICIS PHARMACEUTICAL CORP (MRX)
Mes dernières consult.
Most popular
  Report  
SummaryNewsCompany 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Medicis Pharma Shares Fall on Q-Med Lawsuit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/09/2012 | 09:03pm CEST
   By Anna Prior 
 

Q-Med Inc., a division of pharmaceutical company Galderma, has sued Medicis Pharmaceutical Corp. (>> Medicis Pharmaceutical Corp) over the contracts for several dermal filler products in connection with Medicis's planned merger with Valeant Pharmaceuticals International Inc. (>> Valeant Pharmaceuticals Intl Inc).

Medicis shares recently fell 3.3% to $41.91 on heavy volume as investors worried about the impact the lawsuit could have on the merger. The stock has risen 26% for the year, jumping 38% after Valeant announced a $44-a-share offer price.

In its quarterly filing, Medicis said Q-Med is alleging breach of obligation regarding its licensing and contracts for Restylane and Perlane, and it has the right to withhold consent to a change-of-control of Medicis that would result in a transfer to Valeant of the exclusive rights to market and sell the dermal filler products.

"We think their position is without merit," said Laurie Little, vice president of investor relations for Valeant. "We're going to go ahead and vigorously defend ourselves."

Medicis also said in the filing that the merger agreement doesn't require the consent of Q-Med, and Ms. Little added that at this point, Valeant is still moving forward with the transaction.

In September, Valeant agreed to buy Medicis for $2.6 billion, the latest in a string of acquisitions that have transformed the Canadian drug maker into a multibillion-dollar global company. Valeant focuses on branded pharmaceuticals, branded generics and over-the-counter products, and it specializes in neurology and dermatology.

Write to Anna Prior at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article
ChangeLast1st jan.
MEDICIS PHARMACEUTICAL CORP --End-of-day quote.
QMED, INC. -90.00% 1.0E-5 Delayed Quote.900.00%
VALEANT PHARMACEUTICALS INTL INC 0.00% 21.94 Delayed Quote.-16.26%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDICIS PHARMACEUTICAL COR
2016TIMELINE : Shakeup at Valeant as longtime CEO Pearson leaving
RE
2015From pilot to profit-maker, Valeant's pharmacy rose quickly
RE
2012Garmin to Join S&P 500 Index, Replacing RR Donnelley
DJ
2012MEDICIS PHARMACEUTICAL CORP : Valeant Pharmaceuticals Announces New Management A..
PR
2012MEDICIS PHARMACEUTICAL CORP : Valeant Pharmaceuticals Receives FTC Clearance For..
PR
2012Medicis Pharma Shares Fall on Q-Med Lawsuit
DJ
2012MEDICIS PHARMACEUTICAL CORP : Medicis Declares Cash Dividend
PU
2012MEDICIS PHARMACEUTICAL CORP : Law Office of Brodsky & Smith, LLC Announces Inves..
BU
2012MEDICIS PHARMACEUTICAL CORP : Faruqi & Faruqi, LLP Is Seeking More Cash For The ..
BU
2012U.S. HOT STOCK FUTURES : Hot stocks to watch
DJ
More news
Chart MEDICIS PHARMACEUTICAL COR
Duration : Period :
Medicis Pharmaceutical Cor Technical Analysis Chart | MRX | US5846903095 | 4-Traders